NMOSD

Serum GFAP levels showed consistent correlations with disease activity and the largest area under the ROC curve to differentiate attacks from remissions in individuals with NMOSD.

The basis for the approval was data from the phase 3 SAkuraSky and SAkuraStar studies, which combined included more than 170 patients who were treated with either satralizumab or placebo.

NeuroMetrix will be evaluating the effectiveness of the transcutaneous electrical nerve stimulation platform in pain relief for patients with neuromyelitis optica spectrum disorder.

Although existing research has shown structural differences between multiple sclerosis and neuromyelitis optica spectrum disorder in following optic neuritis, the new report also covers non–optic neuritis eyes.

The clinical research director at the UCSF Multiple Sclerosis Center shared some of the takeaways from his research for the clinical community of specialists treating patients with NMOSD.

NMOSD is associated with elevated levels of the pleiotropic cytokine interleukin-6, making the cytokine an apt therapeutic target.

The clinical research director at the UCSF Multiple Sclerosis Center discussed the findings of the long-term open-label assessment of inebilizumab in neuromyelitis optica spectrum disorder.

Patients in the randomized controlled trial and the open-label extension treated with inebilizumab experienced similar rates of being attack-free, extending as far as 4 years.

The findings were consistent with the established safety profile for eculizumab in other non-neurologic indications, according to study authors.